Marc Simon, MD
Advanced Heart Failure and Transplant Cardiology · San Francisco, CANPI 1346215449
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,681 of the $114,392 with a category attached, or 60.0%. 17 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 29.5% of the total.
Across 239 payments — averaging $478.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$34K
- Merck$31K
- United Therapeutics Corporation$20K
- Actelion Pharmaceuticals, Ltd$15K
- Bayer$11K
- Chiesi USA, Inc.$960
- plus $3K from 11 others
Across 71 payments — averaging $7557.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$189K
- United Therapeutics Corporation$127K
- GSK$79K
- E.r. Squibb & Sons, L.L.C.$61K
- Actelion Pharmaceuticals, Ltd$35K
- Amgen$26K
- plus $19K from 2 others
What the payments were for
- Consulting fees$68,68160%
- Speaking & faculty fees$2,1002%
- Travel & lodging$30,74627%
- Food & beverage$12,82511%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 79 | $33,756 |
| Merck | 48 | $30,647 |
| United Therapeutics Corporation | 58 | $20,062 |
| Actelion Pharmaceuticals, Ltd | 8 | $15,121 |
| Bayer | 17 | $11,238 |
| Chiesi USA, Inc. | 3 | $960 |
| Sandoz | 10 | $579 |
| Amgen | 2 | $454 |
| Impulse Dynamics (USA) Inc. | 2 | $440 |
| Kerecis Limited | 2 | $327 |
| Abbott | 2 | $291 |
| Johnson & Johnson(2 entities) | 2 | $196 |
| Edwards Lifesciences | 1 | $175 |
| Liquidia Technologies, Inc. | 2 | $87 |
| Novartis | 1 | $23 |
| Genentech, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$16,664
- NONE$15,032
- OPSUMIT$12,077
- Adempas$10,746
- OPSYNVI$5,190
- WINREVAIR$2,889
- Kerecis SurgiClose$787
- Kerecis Omega3 Marigen$520
- OPTIMIZER SMART SYSTEM$412
- TYVASO$340
- ORENITRAM$206
- Kerecis GraftGuide$197
- CARDIOMEMS$178
- MITRIS RESILIA Mitral Valve$175
- Kerecis Omega3 SurgiClose$130
- BOSENTAN$117
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$114
- TREPROSTINIL$107
- REMODULIN$101
How this compares
$114,392 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 53 | $1,261,333 |
| Tyvaso DpiTreprostinil | 42 | $1,253,947 |
| OpsumitMacitentan | 34 | $425,697 |
| AdempasRiociguat | 14 | $189,442 |
| JardianceEmpagliflozin | 44 | $53,331 |
| Tadalafil | 28 | $31,299 |
| Ambrisentan | 12 | $16,619 |
| Praluent PenAlirocumab | 15 | $7,083 |
| Tacrolimus | 13 | $1,352 |
| Sildenafil Citrate | 13 | $446 |
| Spironolactone | 41 | $294 |
| Metoprolol Succinate | 14 | $284 |
| Rosuvastatin Calcium | 13 | $190 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $75 |
| Losartan Potassium | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $33,756 | $1,687,03087 claims |
| BayerAdempas | $11,238 | $189,44214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Francisco
- Teresa de MarcoSan Francisco$366K
- Liviu KleinSan Francisco$223K
- Michael MartynSan Francisco$89K
- Shweta MotiwalaSan Francisco$50K
- Mandar ArasSan Francisco$41K
- Jared HerrSan Francisco$12K
- Michael PhamSan Francisco$9K
- Pooja PrasadSan Francisco$8K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.